{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"278"}],"title":"Never-positive"},{"measurements":[{"groupId":"OG000","value":"66"}],"title":"Ever-positive"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"344"}],"units":"Participants"}],"description":"ADA against avelumab in serum samples was determined and reported separately for ADA never positive and ADA ever positive participants. Participants were considered ADA ever-positive if they had at least one positive ADA result at any time point during study and were otherwise considered negative. Data for this outcome measure was not planned to be collected and analyzed for reporting arm \"Best Supportive Care\", since avelumab was not administered in this arm.","groups":[{"description":"Participants received an intravenous (IV) infusion of 10 milligrams per kilograms (mg/kg) of Avelumab along with BSC, on Day 1 and 15 of each 28 days treatment cycle, until confirmed disease progression, participant refusal, lost to follow up, unacceptable toxicity, or study termination by the sponsor, whichever occurred first. BSC was administered as per the treating physician. Participants were followed up until death, end of the study or withdrawal of consent, whichever comes first, regardless of initiation of new anti-cancer therapy.","id":"OG000","title":"Avelumab + Best Supportive Care (BSC)"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"The immunogenicity analysis set included all participants who had received at least one dose of study drug and who had at least one ADA sample collected for avelumab in the avelumab containing arm.","reportingStatus":"POSTED","timeFrame":"From randomization up to the 30-Day Follow-up visit (maximum duration of up to approximately 68 months)","title":"Number of Participants With Anti-Drug Antibodies (ADA) Against Avelumab by Never and Ever Positive Status","type":"SECONDARY","unitOfMeasure":"Participants"}